cagri and tirzepatide together Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes Tirzepatide Shows 25% Weight Loss

Persistent Dysfunction: These night-time #metabolic disturbances persist even after significant weight loss and a reduction in liver fat, suggesting that #nocturnal dysfunction may be a primary driver of the disease, not just a symptom

Therefore, eat before drinking to slow alcohol absorption

White adipose tissues store fats in the body and cause body disfigurement in obesity

Many people find that after 3 to 4 weeks of consistent dietary changes and bioavailable supplementation, they feel a noticeable difference in their daily energy and overall resilience.

for long-term metabolic outcomes Biohacker Microdosing Dose: 0.5 1 mg every 3 days (variant 5 mg pen = 1530 clicks / variant 10 mg pen = 510 clicks / variant 15 mg pen = 510 clicks) Duration: 4 8 weeks Frequency: Every 3 days Cycle Interval: Repeat after 1 month Goal / Description: Used experimentally to assess mild appetite control and metabolic priming Maintenance Phase Dose: 2.5 5 mg (variant 5 mg pen = 76152 clicks / variant 10 mg pen = 2550 clicks / variant 15 mg pen = 2550 clicks) Duration: Variable Frequency: 1 weekly Cycle Interval: Continuous Goal / Description: Sustain achieved body composition and metabolic balance

Side effects are generally mild or absent